The UroVysion FISH test examines cells shed into urine for chromosome changes associated with urothelial cancer, especially bladder cancer. Unlike urine cytology, which depends on how abnormal cells look under a microscope, UroVysion uses fluorescent DNA probes to count selected genetic signals inside cell nuclei. The assay targets chromosomes 3, 7, and 17 and the 9p21 region, where the CDKN2A/p16 tumor-suppressor locus is located. A positive result can increase concern for urothelial carcinoma, but it is not the same as a tissue diagnosis and does not by itself establish tumor grade, stage, or location. The test is often used as an adjunct when evaluating hematuria, following people with a history of bladder cancer, or clarifying an equivocal cytology result. Interpretation is strongest when the FISH result is considered together with cystoscopy, cytology, symptoms, treatment history, and the person’s baseline risk of recurrence.
- UroVysion is a urine fluorescence in situ hybridization, or FISH, assay that looks for selected chromosome abnormalities in urothelial cells.
- The standard probe set evaluates chromosomes 3, 7, and 17 plus deletion of the 9p21 locus.
- A positive UroVysion result raises suspicion for urothelial cancer but does not prove that a visible bladder tumor is present.
- FISH can be particularly helpful when urine cytology is atypical or suspicious, but the two tests measure different biological features.
- Cystoscopy and, when needed, biopsy or transurethral resection remain essential for confirming and characterizing bladder cancer.
Table of Contents
- What the UroVysion FISH Test Measures
- How UroVysion Is Performed and Scored
- What a Positive UroVysion Result Means
- Negative, Equivocal, and Invalid Results
- UroVysion Versus Urine Cytology
- When UroVysion Is Used in Bladder Cancer Care
- Follow-Up After an Abnormal FISH Result
What the UroVysion FISH Test Measures
UroVysion is a multicolor fluorescence in situ hybridization assay. FISH uses short DNA probes that bind to specific chromosome regions. Fluorescent labels make those probes visible under a specialized microscope, allowing a trained laboratory professional to count how many copies of each target appear in selected urinary cells.
The classic UroVysion probe set examines four targets:
- Chromosome 3 centromere: extra copies can indicate aneuploidy, an abnormal chromosome number.
- Chromosome 7 centromere: gains are another recurrent cytogenetic change in urothelial carcinoma.
- Chromosome 17 centromere: gains may occur with broader chromosomal instability.
- 9p21 locus: loss of both copies can indicate deletion in a region containing the CDKN2A/p16 tumor-suppressor gene.
The assay therefore does not sequence the entire tumor genome. It asks whether cells in the urine show a predefined pattern of gains or losses that is more common in urothelial cancer than in normal urothelium. The test is cell based: enough intact, interpretable urothelial cells must be present for analysis.
This differs from the urine cytology test. Cytology evaluates nuclear size, shape, chromatin, cell arrangement, and other morphologic features. FISH evaluates chromosome signals. A cell can look only mildly atypical while carrying a molecular abnormality, or it can look reactive from inflammation without having the UroVysion pattern.
UroVysion is primarily associated with urothelial carcinoma, which most often arises in the bladder but can also occur in the renal pelvis or ureter. A positive urine result therefore identifies an abnormal urothelial-cell signal; it does not identify the exact anatomic site by itself.
How UroVysion Is Performed and Scored
The specimen is usually voided urine collected according to the laboratory’s instructions. The laboratory concentrates urinary cells, fixes them onto slides, applies the fluorescent probes, allows the probes to hybridize with their chromosome targets, and then examines selected nuclei under fluorescence microscopy. Pre-analytical details such as collection, preservation, transport, cellularity, and slide quality matter because degraded or sparse cells can make interpretation difficult.
For the standard kit criteria described in the literature, the laboratory evaluates morphologically abnormal cells and looks for multiple chromosome gains or complete loss of the 9p21 signal. A commonly cited positive pattern is at least four cells showing gains of two or more of chromosomes 3, 7, and 17, or at least 12 cells showing homozygous deletion of 9p21. Laboratories follow the current validated assay instructions and quality rules, so the report issued by the performing laboratory—not a threshold copied from another setting—should guide interpretation.
The scoring concept is easier to understand with an example. A normal diploid cell generally has two signals for each chromosome target. If one suspicious nucleus has three or more signals for chromosomes 3 and 7, that cell shows polysomy for multiple targets. One abnormal cell is not enough for the standard positive call; the assay requires a defined number of abnormal cells so that random technical artifacts or isolated unusual cells are less likely to drive the result.
Reports may use categories such as positive, negative, equivocal, atypical, or insufficient/invalid depending on the laboratory and specimen. The exact wording should be read together with any comment about cell number, probe pattern, specimen adequacy, or previous results.
The procedure is analytically more complex than a rapid dipstick-style marker. It needs specialized equipment and trained personnel. That complexity is one reason UroVysion is usually used for selected diagnostic questions rather than as a general population screening test.
What a Positive UroVysion Result Means
A positive UroVysion result means that the urine contains enough cells meeting the assay’s predefined chromosomal abnormality criteria. In a person being evaluated for possible urothelial cancer, this increases suspicion that a neoplastic urothelial clone is present somewhere in the urinary tract.
What it does not mean is equally important. A positive FISH result does not establish:
- the exact location of a tumor;
- whether a lesion is visible on cystoscopy;
- the tumor’s histologic grade or pathologic stage;
- whether muscle invasion is present;
- or whether immediate treatment is required.
Those questions require direct evaluation. A visible bladder lesion is generally sampled or resected so that a pathologist can examine tissue. Imaging or upper-tract endoscopy may be needed if there is concern for disease in the ureter or renal pelvis.
The probability that a positive result represents cancer depends on why the test was ordered. In a patient with previous high-grade non-muscle-invasive bladder cancer, the pretest probability of recurrence can be substantial, making a new positive result more concerning. In a low-risk person with no prior urothelial cancer, the same molecular signal has a different positive predictive value.
Some patients have a positive UroVysion result before cystoscopy shows a recurrence. This has been called an “anticipatory positive” result. It may reflect molecular changes in exfoliated cells before a lesion becomes endoscopically obvious, but it is not a guarantee that cancer will appear. The appropriate response is risk-adjusted surveillance rather than assuming that an invisible tumor has been proven.
The pattern responsible for positivity can also matter to the laboratory interpretation. Polysomy involving several chromosomes reflects a different cytogenetic event from isolated homozygous loss of 9p21. Neither pattern, however, provides a complete molecular portrait of the tumor. A positive report may therefore support the presence of an abnormal urothelial clone without predicting how quickly it will grow or whether it will invade muscle. The result should not be used as a surrogate for stage.
UroVysion can also remain abnormal around the time of treatment or in complex surveillance settings. Intravesical therapy, prior resections, timing of collection, and the person’s cancer biology all matter. A positive result should therefore be interpreted by the treating urologist alongside the complete surveillance record.
Negative, Equivocal, and Invalid Results
A negative UroVysion result means that the analyzed cells did not meet the assay’s positive criteria. It lowers concern in the right clinical context, but it cannot rule out urothelial cancer. Tumors may shed too few abnormal cells, low-grade tumors may have less pronounced chromosomal changes, or the specific tumor may not carry the targeted abnormalities.
The test’s sensitivity is not uniform across all bladder cancers. Like many urine biomarkers, UroVysion generally performs better for biologically aggressive or higher-grade disease than for low-grade papillary tumors. This matters in surveillance because a negative test may be more reassuring for high-grade recurrence than for small low-grade recurrence, yet it still does not justify ignoring scheduled cystoscopy in a patient whose risk category requires it.
An equivocal result usually means that findings approach a cutoff or show an abnormal pattern that does not clearly fulfill the laboratory’s validated definition. Different laboratories may use specific interpretive comments for borderline patterns. Repeating the specimen can be useful when the uncertainty is technical or due to low cellularity, but the need for repeat testing depends on clinical risk.
An invalid or insufficient result is not a negative result. It may occur when there are too few suitable cells, poor preservation, excessive degeneration, technical failure, or another quality problem. The report may recommend recollection. If cancer suspicion is high, clinicians generally do not delay necessary cystoscopy or imaging simply to obtain another biomarker sample.
A false-negative result is possible whenever cancer is present but the urine sample fails to contain enough detectable marker signal. That is why FISH belongs within a diagnostic pathway rather than outside it.
UroVysion Versus Urine Cytology
UroVysion and cytology are complementary rather than redundant. Cytology is especially valued for its high specificity for high-grade urothelial carcinoma when interpreted by experienced cytopathologists. Its weakness is sensitivity, particularly for low-grade tumors. FISH uses objective chromosome targets and can detect some cancers missed by cytology, although it can also produce positive findings that are not confirmed immediately by cystoscopy.
| Feature | UroVysion FISH | Urine cytology |
|---|---|---|
| Main signal | Chromosome copy-number changes and 9p21 loss | Cell morphology |
| Specimen | Urinary urothelial cells | Urinary cells |
| Strength | Molecular evidence that can complement equivocal morphology | High specificity for convincing high-grade malignant cytology |
| Limitation | Cost, specialized processing, false positives, and imperfect sensitivity | Low sensitivity for low-grade tumors and interpretive variability |
| Clinical role | Adjunct in selected diagnostic or surveillance settings | Established adjunct to cystoscopy, particularly for high-grade disease |
When cytology is atypical, the pathologist has seen changes that are not fully normal but are insufficient for a definitive high-grade cancer diagnosis. In this setting, FISH can sometimes help stratify concern. A positive FISH result adds molecular evidence and may prompt closer evaluation; a negative result can be reassuring but does not erase clinical risk.
When cytology is suspicious or positive for high-grade urothelial carcinoma, a negative UroVysion test should not automatically override the cytology. High-grade cytology is clinically important, and the next step may include repeat cystoscopy, enhanced cystoscopy, random or directed bladder biopsies, prostatic urethral evaluation in selected men, and upper-tract assessment depending on the clinical scenario.
Conversely, positive FISH with negative cytology may represent a molecular abnormality not yet producing unmistakably malignant cells. Neither test should be treated as a tie-breaker without considering cystoscopy and risk history.
Specimen timing can contribute to disagreement as well. Cytology and FISH are both dependent on which cells happen to be shed into that urine sample, and shedding is intermittent. A repeat specimen may therefore produce a different result even when the underlying bladder biology has not changed. This is especially relevant when the first sample is sparsely cellular or collected near a procedure or treatment. Clinicians interpret serial results as trends only when collection conditions and the clinical setting are comparable.
When UroVysion Is Used in Bladder Cancer Care
UroVysion has been used in two broad settings: evaluation of patients with hematuria or suspected urothelial cancer, and surveillance of patients previously diagnosed with bladder cancer. Its exact place varies by country, regulatory labeling, guideline, laboratory access, and individual risk.
In hematuria evaluation, the test can add information, but it does not replace a complete risk-based workup. Visible or persistent microscopic blood in the urine can have many causes. People at meaningful risk of urothelial malignancy may still need cystoscopy and upper-tract imaging even when a urine marker is negative.
In surveillance, UroVysion may be useful when routine findings are unclear. Examples include atypical cytology, a negative or equivocal cystoscopy in someone with substantial recurrence risk, or concern about response after intravesical treatment. Recent systematic reviews of urinary biomarkers conclude that these tests may complement cystoscopy rather than replace it across the board.
Another surveillance option is an RNA-expression assay such as the Xpert Bladder Cancer Monitor test. Protein-based tests such as NMP22 ask different biological questions again. There is no reason to expect all urine markers to agree because they measure different features and use different thresholds.
The greatest value of a marker may be in a carefully designed risk-adapted pathway: identifying a subset of patients who need more urgent evaluation or, in validated protocols, helping reduce some low-value invasive procedures. Evidence for those strategies continues to evolve, and a biomarker should not be used outside its intended context simply because it is noninvasive.
Follow-Up After an Abnormal FISH Result
Follow-up begins by confirming the clinical context. The urologist reviews why the test was ordered, the patient’s previous tumor grade and stage, smoking and hematuria history, recent cystoscopy, cytology category, intravesical treatments, imaging, and the laboratory’s detailed FISH pattern.
If FISH is positive and cystoscopy shows a suspicious lesion, transurethral resection or biopsy is usually the decisive next step. Tissue establishes whether the lesion is malignant and provides grade and stage information that a urine test cannot supply.
If FISH is positive but standard cystoscopy is negative, management is individualized. Higher-risk patients may need earlier repeat cystoscopy, enhanced visualization, repeat cytology, directed or mapping biopsies, or evaluation of the upper urinary tract. A repeated positive molecular finding can strengthen concern, but it still does not substitute for localization and histologic confirmation.
If cytology is atypical and FISH is negative, the clinician considers whether the overall cancer risk is low enough for routine follow-up or whether the atypia remains unexplained. Infection, stones, instrumentation, treatment effects, and specimen quality may be reviewed. Persistent atypia can justify repeat cytology or further urologic evaluation even with a negative FISH result.
Patients should contact their clinician promptly for visible blood in the urine, worsening urinary symptoms, flank pain, unexplained weight loss, or other new concerns rather than waiting for a scheduled biomarker recheck. A urine molecular test is one data point in a broader cancer evaluation, and symptoms can change the urgency of follow-up.
The practical question after any UroVysion report is therefore: “What does this result change in my surveillance or diagnostic plan?” The safest interpretation connects the chromosome finding to a specific next action instead of treating positive or negative as a final diagnosis.
A positive FISH result can occasionally precede a tumor that becomes visible on later cystoscopy, a pattern sometimes described as an anticipatory positive result. That possibility is clinically relevant during surveillance, but it should not be used to declare recurrence without localization. The appropriate response is risk-based follow-up, which may include closer cystoscopic assessment, repeat urine testing, upper-tract evaluation, or biopsy when indicated.
References
– UroVysionTM Fluorescence In Situ Hybridization in Urological Cancers: A Narrative Review and Future Perspectives. 2022 (Review) – Bladder Cancer, a Cytogenomic Update 2024 (Review) – Noninvasive Tests for Bladder Cancer Detection and Surveillance: A Systematic Review of Commercially Available Assays 2024 (Systematic Review) – Urinary Biomarkers in Bladder Cancer: FDA-Approved Tests and Emerging Tools for Diagnosis and Surveillance 2025 (Review) – Evaluating diagnostic performance of urinary biomarkers in the surveillance of non-muscle invasive bladder carcinoma: A systematic review 2025 (Systematic Review) – Diagnostic Performance of Urinary Biomarker Tests in Detecting Bladder Cancer: A Systematic Review, Meta-analysis, and Network Meta-analysis 2026 (Systematic Review)
Disclaimer
This article is for general educational information and does not provide medical advice, diagnosis, or treatment. UroVysion results should be interpreted by a qualified clinician together with cystoscopy, cytology, pathology, imaging, symptoms, and prior cancer history. Do not change a bladder cancer surveillance plan based on a urine FISH result alone.
